BioCity Biopharma Completes Enrollment for IgA Nephropathy Cohort in Phase II Trial of SC0062, Aiming to Target CKD and Proteinuria

BioCity Biopharma Completes Enrollment for IgA Nephropathy Cohort in Phase II Trial of SC0062 Company: BioCity Biopharma Indication: IgA nephropathy (IgAN), chronic kidney disease (CKD), diabetic kidney disease (DKD) Drug: SC0062 Trial Phase: Phase 2 NCT ID: Not provided Overview BioCity Biopharma has announced the successful completion of patient enrollment for the IgA nephropathy (IgAN) cohort..

  • format_list_bulleted Pharmacology/BS
  • · 2024. 2. 28.
  • textsms

BioCity Biopharma Completes Enrollment for IgA Nephropathy Patients in Phase II Trial of SC0062, Advancing Chronic Kidney Disease Treatment

BioCity Biopharma Completes Enrollment for IgA Nephropathy Patients in Phase II Trial of SC0062 Advancing Chronic Kidney Disease Treatment Overview Company: BioCity Biopharma Indication: Chronic kidney disease (CKD), IgA nephropathy (IgAN), diabetic kidney disease (DKD) Drug: SC0062 Trial Phase: Phase 2 NCT ID: N/A Background Headquartered in Wuxi, China, BioCity Biopharma is steadfast in its de..

  • format_list_bulleted Pharmacology/BS
  • · 2024. 2. 27.
  • textsms